A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026

Cogent Biosciences (COGT) is in focus after sharing new preclinical data on its KRAS and ErbB2 drug candidates at the AACR 2026 meeting in San Diego, highlighting selectivity, activity and safety signals. See our latest analysis for Cogent Biosciences. The AACR presentations land at a time when Cogent Biosciences’ share price, now at $36.81, has seen a 1 day share price return of 1.85% and a year to date share price return of 5.96%. The 1 year total shareholder return is around 7x, pointing to strong momentum built over a longer period despite some softer shorter term moves. If this kind of oncology pipeline story interests you, it can be worth widening your watchlist to include other potential growth names uncovered by the 33 healthcare AI stocks With Cogent Biosciences now at $36.81 and trading at a sizeable discount to the average analyst price target of $54.17, the key question is whether this is an overlooked oncology story or whether the market is already pricing in future growth. Price to Book of 10.8x: Is it justified? Cogent Biosciences is trading on a P/B of 10.8x, which prices the stock very differently depending on whether you compare it with broad biotech peers or a narrower peer set. The P/B ratio compares a company’s market value with its net assets on the balance sheet. For a clinical stage biotech with no meaningful revenue and a net loss of $328.9m, the market is often paying for the pipeline, management track record and future expectations rather than current earnings power. Against the wider US Biotechs industry average P/B of 2.3x, Cogent Biosciences looks expensive, suggesting investors are paying a substantial premium to the sector’s balance sheet values. However, compared to its closer peer group, where the average P/B stands at 28.5x, the same 10.8x multiple sits at a considerable discount, which shows how differently similar stage companies are being priced. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 10.8x (ABOUT RIGHT) However, the story can change quickly if trial readouts disappoint or if Cogent needs to raise fresh capital while still posting a net loss of $328.9m. Find out about the key risks to this Cogent Biosciences narrative. Next Steps With sentiment around Cogent swinging between excitement over the pipeline and concerns about risks and funding needs, it makes sense to review the numbers and context for yourself, including the 1 key reward and 2 important warning signs. Looking for more investment ideas? If Cogent has caught your attention, do not stop there. The right watchlist can make the difference between spotting opportunities early and hearing about them too late. Hunt for overlooked quality by scanning screener containing 25 high quality undiscovered gems, which pair solid fundamentals with under the radar profiles that many investors are not watching yet. Strengthen your defensive side by reviewing the solid balance sheet and fundamentals stocks screener (42 results) to focus on companies with finances that can better support their operations through a range of conditions. Target income focused ideas by checking the 12 dividend fortresses, which highlight companies aiming to combine higher yields with more durable cash flows. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for Free